AbbVie Inc. Liabilities, Fair Value Adjustment
AbbVie Inc. (ABBV) reported Liabilities, Fair Value Adjustment of $0 for the 6-month period ending 2013-06-30, per its 10-Q filed 2013-08-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:LiabilitiesFairValueAdjustment · last filed 2013-08-09
- AbbVie Inc. liabilities, fair value adjustment for the quarter ending 2013-06-30 was $0.00.
- AbbVie Inc. liabilities, fair value adjustment for the quarter ending 2013-03-31 was $0.00.
- AbbVie Inc. liabilities, fair value adjustment for the quarter ending 2012-06-30 was $0.00.
- AbbVie Inc. liabilities, fair value adjustment for the quarter ending 2012-03-31 was $0.00.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month |
|---|---|---|
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $0.00 10-Q · filed 2013-08-09 |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-08 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $0.00 10-Q · filed 2013-08-09 |
| 2012-03-31 | $0.00 10-Q · filed 2013-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |